Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

5657 - Fatigue prevalence and adherence to treatment. A real-world data survey and mathematical model application.

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Daniel Vorobiof

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

D.A. Vorobiof, E. Malki, I. Deutsch, M. Bivasbenita

Author affiliations

  • Med Onc, Sandton Oncology Centre, 2199 - Sandton/ZA
More

Resources

Abstract 5657

Background

Fatigue is a common symptom reported by cancer patients (pts) and has been previously documented to affect patient’s quality of life.

Methods

A real-world data survey was designed to evaluate, from the pts perspective, the fatigue effect and treatment adherenceA survey was created in a digital format. This was sent randomly and replied anonymously by users of the Belong app a dedicated social network for cancer pts and their caregivers. Belong leveraged both push notifications as well as DPROs (Digital patients reported outcome feature) which appeared on user’s apps dashboards for their increased engagement.

Results

505 replies were received from pts (85%) and caregivers (15%). The data was then extracted from the digital platform and analysed. A statistical mathematical predictive model was utilized. A machine learning analytical model was programmed to obtain the results. The most common diagnoses were Breast Cancer (all stages, 34.5%), lung (10.1%) and colorectal cancer (7.7%). 67.1% of the pts were on active treatment at the time of the survey and 11.5% finished the treatment less than 6 months before. 66% of the pts experienced daily fatigue (described as mild, moderate and severe) and 17.2% experienced it weekly. As a direct result of fatigue, 10.1% of all pts reported that their ongoing treatments were delayed, stopped or changed (poor adherence). 137 (27%) of the total number of replies (mainly advanced breast and lung cancers pts) reported severe fatigue and 19% of them confirmed poor treatment adherence. However, better adherence was seen in the subgroup of pts which experienced mild to moderate fatigue.

Conclusions

This survey describes the prevalence and adverse impact of severe fatigue present in certain cancer pts subgroups (advanced breast and lung cancers) which can alter significantly their adherence to planned treatments. Uniquely, while poor treatment adherence was observed in some cancer diagnosis, most of patients who experienced mild to moderate fatigue maintained their treatment schedule. Effective strategies and efforts should aim to solve this common side effect and its deleterious consequences.

Clinical trial identification

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.